紫杉醇脂质体联合奈达铂同步放化疗治疗中晚期宫颈鳞癌

[目的]探讨紫杉醇脂质体联合奈达铂同步放化疗治疗中晚期宫颈鳞癌患者的疗效及不良反应。[方法]对26例病理确诊的Ⅱb～Ⅳa期宫颈鳞癌患者采用盆腔外照射+高剂量率腔内后装放疗及同期化疗,化疗方案为:紫杉醇脂质体40mg/m2+奈达铂20mg/m2,每周1次,共6次。观察近期疗效、1、2、3年生存率及化疗、放疗不良反应。[结果]完全缓解(CR)20例(76.9%),部分缓解(PR)5例(19.2%),稳定(SD)1例(3.8%),进展(PD)0例,有效率(RR)为96.2%(25/26)。1、2、3年生存率分别为96.2%、88.5%、84.6%。不良反应主要为骨髓抑制、脱发及胃肠道反应,但均能耐受;放疗远期并发症发生率低且较轻。[结论]紫杉醇脂质体联合奈达铂同步放化疗治疗中晚期宫颈鳞癌的疗效好,不良反应可耐受,患者依从性高。

Concurrent Chemoradiotherapy of Paclitaxel Liposome and Nedaplatin in the Treatment for Advanced Cervical Squamous Cell Carcinoma

[Purpose]To investigate the efficacy and toxicity of concurrent chemoradiotherapy of paclitaxel liposome and nedaplatin in the treatment for advanced cervical squamous cell carcinoma.[Methods]Twenty-six cases with cervical squamous cell carcinoma stageⅡb～Ⅳa were treated with pelvic cavity external irradiation and high dose rate intracavity brachytherapy,concurrent with chemotherapy(paclitaxel liposome 40mg/m2 with nedaplatin 20mg/m2,once for every week,with total 6 times).The 1-,2-,3-year survival rate and toxicity of chemoradiotherapy were observed.[Results]Complete response(CR)was found in 20 cases(76.9%);partial response(PR),5 cases(19.2%);stable disease(SD),1 case(3.8%);progress disease(PD),none,with response rate of 96.2%(25/26).The 1-,2-,3-year survival rate was 96.2%,88.5%,84.6%,respectively.The toxicities including marrow depression,alopecia and gastrointestinal toxicities were tolerable.The longterm complication of radiotherapy was mild.[Conclusion]Concurrent chemoradiotherapy of paclitaxel liposome and nedaplatin in the treatment for advanced cervical squamous cell carcinoma is effective and tolerable,with good compliance.